TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07226830: Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG

Sponsor: BioSensics · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 25 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,237,600

Rescue Site Savings

+$4,780,800

Unlock Full NCT07226830 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07226830 Rescue Dossier →